AEONIAN BIOTECH NETHERLANDS BV Profile

We introduce a new concept for the research antibody market:
Our mission is to eradicate wasted R&D expenses caused by poorly characterised, unstable, inconsistently performing, or no longer available immunological reagents. Among the large amounts of commercially available antibodies to any one specific protein/biomarker, we identify those few that meet the highest quality standards. 

We use proprietary selection criteria, our Aeonian Rating®, to identify the best candidate antibodies. This new quality standard is reminiscent to the Michelin stars for restaurants. Only ratings of 70 and higher will make it to our catalogue, dismissing the majority of research antibodies on the market. This approach makes us unique!

Our focus is on recombinant antibodies, because they are no longer dependent on a potentially unstable hybridoma, and they can be remade indefinitely without running the risk of molecular changes in the antibody. Our rating rewards scientifically sound quality data, no matter how few, a proper formulation, when offered purified in known mg, well characterised and unique epitopes, and data to demonstrate selectivity.

A number of our antibodies have rated the absolute maximum: 100

These winners meet all quality criteria that we can think of, and should be deemed the absolute elite of our selection.

You can find our Aeonian AntibodiesTM here: https://aeonianbiotech.com/aeonian-antibodies/

Tag antibodies are extremely popular, as the tag can be genetically introduced to proteins for which antibodies are hard to make or find. Now they are available as recombinant antibodies and against competing pricing!

You can find our Recombinant Epitope Tag Antibodies here: https://aeonianbiotech.com/recombinant-epitope-tag-antibodies/